Patient Guide · Updated November 2026

Your Doctor Won’t Increase Your GLP-1 Dose: What to Do

You have been on the same GLP-1 dose for weeks. Your appetite is creeping back. You feel like the medication is losing its edge. But when you ask your provider about moving up, they say no. This is one of the most frustrating experiences on Mounjaro, Ozempic, or Wegovy, and it is more common than you think. Here is why it happens, when it actually makes sense, and exactly what to do about it.

Why Your Doctor Is Holding Your Dose

Before you get frustrated with your provider (I have been there), it helps to understand the most common reasons they pump the brakes on titration.

1. Your Side Effects Have Not Resolved

This is the number one reason. If you are still dealing with nausea, vomiting, diarrhea, or constipation at your current dose, most providers will not increase until those symptoms settle. Increasing the dose while your GI system is still adjusting usually makes things worse, not better.

The FDA labels set 4 weeks as the minimum, not a deadline. The Mounjaro label and Zepbound label raise the dose in 2.5 mg steps “after at least 4 weeks” on the current dose. The Wegovy label escalates every 4 weeks and says that if a patient does not tolerate a dose during escalation, the prescriber can consider delaying the next step for 4 weeks. So if you spent most of the last month with significant nausea, a longer hold is in line with the label.

2. Insurance Rules

If your GLP-1 is covered by insurance, your plan may have prior authorization rules, quantity limits, or step therapy (trying a different drug first). Some plans also require proof of weight loss to keep approving coverage. These rules vary a lot by plan.

These rules are not your doctor’s choice. Your provider may agree that you need a higher dose but still have to get the insurer’s approval first. Ask your provider or your plan exactly which rule applies.

Label Titration Schedules

Medication	Label dose steps	Minimum time per step
Mounjaro (tirzepatide, type 2 diabetes)	2.5 mg start, then 2.5 mg increases up to 15 mg if more glucose control is needed	At least 4 weeks
Zepbound (label, tirzepatide)	2.5 mg start, then 2.5 mg increases. Maintenance 5, 10, or 15 mg	At least 4 weeks
Ozempic (semaglutide, type 2 diabetes)	0.25 mg, 0.5 mg, then 1 mg and 2 mg if needed	4 weeks at 0.25 mg, then at least 4 weeks per step
Wegovy (semaglutide)	0.25, 0.5, 1, 1.7 mg, then a maintenance dose (usually 2.4 mg)	Every 4 weeks, with an option to delay 4 weeks if not tolerated

If your provider holds you well beyond these minimums without a specific medical reason, that is worth a conversation.

3. Too-Fast Titration Concerns

Some providers titrate more slowly than the label minimum. If you moved from 2.5mg to 5mg Mounjaro after 4 weeks, your doctor might want more time at 5mg before moving to 7.5mg.

The main trials (SURMOUNT-1, STEP 1) raised doses every 4 weeks. Real-world practice can move slower, particularly for patients with GI conditions, older patients, or those on several medications.

4. Lab Work or Health Concerns

Your provider might hold your dose if recent bloodwork shows something that needs attention. Elevated lipase or amylase (markers of pancreatic stress), significant changes in kidney function, or thyroid concerns can all prompt a pause. This is your doctor doing their job well, even if it feels like an obstacle.

5. Provider Inexperience With GLP-1 Protocols

Some providers have less experience with GLP-1s. A doctor with a handful of GLP-1 patients may approach titration differently than a clinic that prescribes them every day. Less experience sometimes shows up as extra caution. Not because the provider is bad, but because they are being careful with a medication class they are still getting comfortable with.

When Holding Your Dose Is Actually the Right Call

Here is the part you might not want to hear: sometimes your doctor is right to hold your dose.

Your doctor is probably right if:

You are still losing 1 to 2 pounds per week at the current dose
You have active GI side effects that have not stabilized
Your labs showed something abnormal that needs monitoring
You have been at the current dose for less than 4 weeks
You are not eating enough protein and your muscle mass is dropping (increasing the dose will make this worse)

A key indicator: If the medication is still working (appetite is controlled, weight is trending down, even slowly), there is no clinical reason to increase. The goal is the lowest effective dose, not the highest tolerable one. I learned this the hard way.

My experience: I stayed on 5mg Mounjaro for an extra month because my provider wanted my GI symptoms to settle. I was annoyed at the time. My appetite had started to creep back around week 3, and I felt like I was losing momentum. But looking back, my nausea at 5mg was real. It was not severe, but it was persistent. When I finally moved to 7.5mg with a calm stomach, the transition was much smoother than it would have been otherwise. Sometimes the extra time at a dose is not wasted. It is preparation.

The “My Appetite Is Coming Back” Conversation

This is the most common reason patients push for a dose increase. And it is a legitimate concern. If your appetite suppression is fading and weight loss has stalled for 3 or more weeks, that is clinical information your provider should take seriously.

Here is how to have this conversation effectively:

Track Before You Talk

Show up with data, not just feelings. For 2 weeks before your appointment, track:

Daily food intake (even rough estimates help)
Hunger levels on a 1 to 10 scale, morning and evening
Weight (daily or weekly)
Side effects and their severity

A provider is much more likely to adjust your dose when you can say “My hunger has gone from a 3 to a 7 over the past two weeks, I am eating 400 more calories per day, and my weight has been flat for three weeks” than when you say “I think it stopped working.”

Use Clinical Language

Frame your request in terms your provider’s clinical training responds to:

“My appetite suppression has significantly decreased at this dose level”
“I have had no GI side effects for the past 3 weeks and my weight loss has plateaued”
“Based on the standard titration schedule, I believe I am a candidate for the next dose”
“Can we discuss whether my current dose is still therapeutically adequate?”

Ask Directly What Would Change Their Mind

If your provider says no, ask: “What specific criteria would need to be met for you to consider increasing my dose?” This forces a concrete answer. You might learn that they want to see your next set of labs, or that they want 2 more weeks of stable side effects. Now you have a timeline and a target, not just a vague “let’s wait.”

Tired of waiting? Compare providers who follow standard titration

Compare GLP-1 Providers →

Telehealth Alternatives: Providers Who Follow Standard Titration

If your current provider is consistently slower than the standard titration schedule and you have ruled out legitimate medical reasons, telehealth GLP-1 providers are worth considering. Many of these platforms focus on weight management and may follow the label’s 4-week steps by default.

What to look for in a telehealth GLP-1 provider:

Clear titration schedule published on their website
Dedicated weight management clinicians (not general practitioners adding GLP-1 as a side service)
Monthly check-ins with dose adjustment discussions built into each visit
No unexplained delays beyond the label’s 4-week minimum
Willingness to go back down if a dose is too aggressive (flexibility works both ways)

Several telehealth providers in our provider directory specialize in GLP-1 prescribing and follow evidence-based titration schedules. If you are paying cash, you also avoid insurance approval delays.

For a full comparison of costs between insurance and cash-pay options, see our guide on GLP-1 cash pay vs insurance.

Working Around Insurance Rules

If insurance rules are what is slowing your titration, here are your realistic options:

1. Ask Your Provider to Submit a Prior Authorization or Exception Request

Your doctor can submit a request explaining why the plan’s rule is not appropriate for your case. Results vary by insurer. Helpful documentation can include:

Weight regain or a plateau at the current dose
Return of appetite, with food logs as evidence
Good tolerance of the current dose
Clinical notes supporting medical necessity

2. Appeal a Denial

If the request is denied, you can appeal. Under the Affordable Care Act, most plans must offer an internal appeal and, if that fails, an independent external review. Your provider can write a letter, and you can include a personal statement.

3. Switch to Cash Pay for Dose Flexibility

This is the nuclear option, but it works. If you switch to a cash-pay GLP-1 program, you remove the insurer from the equation entirely. Your provider can titrate on the standard schedule without insurance approval steps.

As of Nov 4, 2026, manufacturer self-pay prices run from $149 a month for the starting Wegovy pill dose to $349 for most Wegovy pen doses on NovoCare, and $299 to $449 for Zepbound on LillyDirect for patients who refill on time. Telehealth visit fees can add to that. That is real money. But if you are stuck at a dose that is no longer effective and insurance is the bottleneck, the math may work in your favor when you factor in months of stalled progress.

4. Ask About Compounded Options

The FDA declared the tirzepatide and semaglutide shortages over in October 2024 and February 2025, and compounding of copies is now tightly limited. Some telehealth platforms still sell compounded versions for cash. They are not FDA-approved, doses are often measured differently from brand pens, and switching should only happen with your prescriber setting the dose.

Questions to Ask Your Provider

Bring this list to your next appointment. These questions are designed to get clear answers, not confrontation.

“What is your standard titration timeline for this medication?” (Tells you if their approach matches the label)
“What specific criteria do you use to decide when a dose increase is appropriate?” (Gets you a concrete target)
“Is there a medical reason specific to my case for holding this dose, or is this a general preference?” (Separates clinical judgment from habit)
“Are there any lab results or health markers you want to see before increasing?” (Gives you action items)
“If my weight loss stalls for another 2 to 3 weeks at this dose, would that change your recommendation?” (Establishes a timeline)
“Would you be open to a shorter hold at this dose if my side effects resolve sooner?” (Shows flexibility on your part)
“Are insurance rules affecting this decision?” (Clarifies whether the delay is medical or administrative)

If you get vague answers to most of these questions, that tells you something about whether this provider is the right fit for your GLP-1 journey.

When to Consider Switching Providers

Switching providers is not something to do lightly. But there are clear signals that your current provider may not be the best fit for GLP-1 management:

They are not following any published titration schedule. The FDA labels give clear dose steps. If your provider cannot explain which protocol they follow, that is a red flag.
They dismiss your appetite returning as “not a real concern.” Breakthrough hunger is a clinical indicator that the current dose may be subtherapeutic. A good provider takes this seriously.
They have very few GLP-1 patients. There is no minimum number, but experience can help with dose decisions.
They cannot answer your titration questions clearly. If you ask the questions above and get deflection instead of answers, your provider may not have the expertise you need.

The Mounjaro dosage guide covers the standard titration schedule in detail. Use it as a reference point when evaluating whether your current timeline is reasonable.

The Bottom Line

A held dose is not always wrong. Sometimes your body genuinely needs more time. But you deserve a provider who can explain why, give you a clear timeline, and respond to clinical evidence (like documented appetite return and weight plateau) with appropriate action.

If your provider is holding your dose for a legitimate medical reason, work with them. Track your symptoms, come prepared, and give it the time they recommend. If the hold is due to insurance rules, explore the workarounds above. And if your provider just seems overly cautious without clear reasoning, it may be time to look at telehealth alternatives that specialize in GLP-1 prescribing.

You are the one living in your body. Advocating for yourself is not being difficult. It is being a good patient.

FAQ

How long should I wait at each GLP-1 dose before expecting an increase?

The FDA labels set a minimum of 4 weeks at each dose for tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy). The Wegovy label allows delaying a step by 4 weeks if a dose is not tolerated. If your provider holds you much longer without a specific medical reason, ask why.

Can I request a specific dose from my doctor?

You can ask, but your provider makes the clinical decision. Coming with documented data (food logs, hunger tracking, weight trends) gives your request more weight than simply asking to go higher. Frame it as sharing information, not demanding a prescription.

What if my insurance requires step therapy but my doctor agrees I need a higher dose?

Your doctor can submit a prior authorization, exception request, or peer-to-peer review. If denied, you can appeal and, for most plans, ask for an independent external review. The other option is switching to cash-pay for the medication, which removes insurance from the process entirely.

Is it safe to stay at a lower dose long-term?

It can be, if it is working and your prescriber agrees. The Zepbound label lists 5 mg, 10 mg, or 15 mg as maintenance doses for weight reduction, and the Wegovy label’s usual maintenance dose is 2.4 mg. Many people do well without reaching the maximum dose. Lower doses can mean fewer side effects and, with some pricing, lower cost. Your prescriber should choose the maintenance dose.

Should I switch to a telehealth provider just for faster titration?

Not just for speed, no. But if your current provider is consistently behind standard titration timelines without a clear medical explanation, a telehealth provider specializing in GLP-1 management may offer better care overall. The goal is not faster titration. The goal is appropriate titration.

Safety note

Mounjaro, Zepbound, Ozempic, and Wegovy carry a boxed warning about thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. The labels also warn about pancreatitis, gallbladder disease, and kidney injury from dehydration. Never raise or change your dose without your prescriber.

What we checked

This AI-assisted public-source desk check reviewed the Mounjaro, Zepbound, Ozempic, and Wegovy labels on DailyMed, the SURMOUNT-1 and STEP 1 trials, HealthCare.gov appeal rules, NovoCare and LillyDirect self-pay prices, and FDA compounding policy dates on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides